Clinical Trial: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Study Type: INTERVENTIONAL
Official Title: Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma
Brief Summary:
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory).Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.Giving tegavivint may help control the disease.
Read more